OSDDMalaria:OSDD Malaria Meeting Sydney 2012: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
Line 39: Line 39:


===Invited===
===Invited===
* [http://www.chiefscientist.nsw.gov.au/About.aspx Mary O'Kane]
* [http://cgkd.anu.edu.au/menus/people_staff&students.php#palombi Luigi Palombi]
* [http://www.csiro.au/Portals/About-CSIRO/Who-we-are/Executive/Executive-Team/AlastairRobertson.aspx Alastair Robertson]
* [http://www.csiro.au/Portals/About-CSIRO/Who-we-are/Executive/Executive-Team/AlastairRobertson.aspx Alastair Robertson]
* [http://www.csiro.au/Organisation-Structure/Flagships/Preventative-Health-Flagship/RichardHead.aspx Richard Head]
* [http://www.csiro.au/Organisation-Structure/Flagships/Preventative-Health-Flagship/RichardHead.aspx Richard Head]

Revision as of 21:16, 18 January 2012

Malaria Home        OSM So Far        Compound Series        Links        Open Source Research Home        Tech Ops        FAQ       


Open Source Drug Discovery for Malaria - February 24th 2012

There will be a one-day meeting on Open Source Drug Discovery for Malaria at The University of Sydney, February 2012.

Location Information

The meeting will take place on the main Camperdown campus of The University of Sydney.

Schedule

Sessions will be titled and arranged shortly, but will be based around questions:

General:

  • How is it best to share chemical and biological data in an open project?
  • What technical barriers prevent open science?
  • Which licence governs an open source drug discovery project?
  • What psychological/professional barriers are there to open science?
  • Is there a danger that open source drug discovery can be hijacked by people taking all the data and patenting them?
  • Who might participate?
  • Who will fund later stages such as clinical trials?
  • Who will manufacture open drugs?


Malaria-specific:

  • Is the GSK arylpyrrole set the best set of compounds to start with?
  • What other compounds are promising starting point? Who might want to work on those compounds?
  • For hit-to-lead, what data are typically needed, and from which assays? What criteria do we apply to compounds as they progress through such assays?

To suggest questions/sessions, either modify this page directly (getting an OWW account is very easy) or contact Mat Todd.

Attending

  • Mat Todd, University of Sydney
  • Paul Ylioja, University of Sydney
  • Paul Willis, MMV
  • Murray Robertson, University of Sydney
  • Saman Habib, CDRI, Lucknow, India
  • Stuart Ralph, Bio21, University of Melbourne

Invited

Potential Invitees

Possibly interesting list maintained here

Streaming/Archiving